# Oral CDX-7108 in Healthy Adults and EPI Subjects

> **NCT05082051** · PHASE1 · COMPLETED · sponsor: **Société des Produits Nestlé (SPN)** · enrollment: 54 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency

## Interventions

- **DRUG:** Part A
- **DRUG:** Part B
- **DRUG:** Part C

## Key facts

- **NCT ID:** NCT05082051
- **Lead sponsor:** Société des Produits Nestlé (SPN)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-11
- **Primary completion:** 2023-03-16
- **Final completion:** 2023-03-16
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082051, "Oral CDX-7108 in Healthy Adults and EPI Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05082051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*